Announced
Completed
Financials
Sources
Tags
United States
Biotechnology
biotechnology company
Single Bidder
Friendly
Domestic
Completed
Private
Acquisition
Majority
Synopsis
Insmed, a global biopharmaceutical company, completed the acquisition of Motus Biosciences, a developer of tools intended for the development of next-generation gene therapies, for $288m.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.